Nicolai D. Raig

Nicolai D. Raig

Auto-generated profile, based on publicly available information

Nicolai D. Raig

Institut für Pharmazeutische Chemie, Goethe-University Frankfurt, Biozentrum, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Science Advances
Verified
Journal Article
Open access
NRNicolai D. Raig
Nicolai D. Raig
KSKatherine J. Surridge
Katherine J. Surridge
MSMarta Sanz-Murillo
Marta Sanz-Murillo
VDVerena Dederer
Verena Dederer
AKAndreas Krämer
Andreas Krämer
SKStefan Knapp
Stefan Knapp
Increased kinase activity of leucine-rich repeat kinase 2 (LRRK2) is associated with Parkinson’s disease (PD). Numerous LRRK2-selective type I kinase inhibitors have been developed, and some have entered clinical trials. Here, to our knowledge, we present the first type II kinase inhibitors that target LRRK2. Targeting the inactive conformation of LRRK2 is functionally distinct from targeting the active-like conformation using type I inhibitors. We designed these inhibitors with a combinatorial chemistry approach fusing selective LRRK2 type I and promiscuous type II inhibitors using iterative cycles of synthesis supported by structural biology and activity testing. Our lead compounds are selective and potent toward both LRRK2 and LRRK1, a close relative of LRRK2. Through cellular assays, cryo–electron microscopy structural analysis, and in vitro motility assays, we show that our inhibitors stabilize the open, inactive LRRK2 kinase conformation. These new conformation-specific compounds will be invaluable as tools to study LRRK2’s function and regulation and expand the potential therapeutic options for PD.

14 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ZZZaile Zhuang
Zaile Zhuang
RTRiley K. Togashi
Riley K. Togashi
PKPatrick Kearney
Patrick Kearney
IPIan Pass
Ian Pass
SSSteven M. Swick
Steven M. Swick
JCJames K. Chen
James K. Chen
Homeodomain-interacting protein kinase 4 (HIPK4) is a dual-specificity kinase that is predominantly expressed in differentiating spermatids, required for sperm development, and a promising target for nonhormonal male contraception. Genetic and functional studies have established an essential role for HIPK4 in spermiogenesis, where it acts at least in part through regulation of the F-actin-scaffolded acroplaxome during spermatid head shaping. The direct molecular targets of HIPK4 and their downstream effectors remain poorly defined, and small-molecule probes would be versatile tools for further investigating HIPK4 functions. Synthetic HIPK4 ligands could also be valuable leads for the development of nonhormonal male contraceptives. Here, we report the discovery of a cyanoquinoline-based series of HIPK4 inhibitors with nanomolar potency. Our lead compounds are selective for HIPK4, both within the HIPK family and across the broader kinome, establishing this scaffold as a useful starting point for probe and lead development. Unexpectedly, we found that a subset of these cyanoquinolines also perturbs HIPK4 proteostasis in a cell type-specific manner. In spermatids, these compounds induce the formation of detergent-insoluble HIPK4 aggregates and promote interactions between this kinase and the autophagy receptor Tax1-binding protein 1 (TAX1BP1). Together, our findings establish cyanoquinoline ligands as a new chemotype for probing HIPK4 biology and advancing male contraceptive discovery.

18 August 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AZAthina Zerva
Athina Zerva
NRNicolai D. Raig
Nicolai D. Raig
ZZZaile Zhuang
Zaile Zhuang
AKAndreas KrämEr
Andreas KrämEr
JDJohannes Dopfer
Johannes Dopfer
THThomas Hanke
Thomas Hanke
Homeodomain-interacting protein kinase 4 (HIPK4) remains an understudied member of the dark kinome. While genetic knockout studies suggest its involvement in spermiogenesis and cutaneous squamous cell carcinoma, whether these cellular functions can be recapitulated by pharmacological inhibition remains to be determined. These investigations are currently hampered by a lack of high-quality chemical tools. To address this, we employed a rational design strategy utilizing macrocyclization of a bosutinib-based scaffold. Systematic optimization led to the discovery of AZ137 (28e), a potent and selective HIPK4 inhibitor (IC50: 11 nM; cellular EC50: 76 nM). AZ137 exhibits exceptional selectivity across three comprehensive orthogonal panels, high solubility, and no detectable cytotoxicity. Its cellular activity was confirmed in cell-based assays of HIPK4-dependent F-actin remodeling. Together with a negative control compound, this probe set provides a foundational framework for validating HIPK4 as a therapeutic target and a high-quality resource to elucidate its roles in normal physiology and disease.

13 June 2026 in ACS Chemical Biology
Verified
Journal Article
Open access
TETheresa A. L. Ehret
Theresa A. L. Ehret
BBBenedict-Tilman Berger
Benedict-Tilman Berger
NRNicolai Raig
Nicolai Raig
FNFelix Nowotka
Felix Nowotka
NMNeele Manik
Neele Manik
MSMartin Schwalm
Martin Schwalm
P21-activated kinases (PAKs) are involved in a broad range of cellular processes and are emerging drug targets. The human PAK family consists of 6 kinases, divided into group I (PAK1-3) and group II (PAK4-6), both families are regulated by distinct activation mechanisms and interaction partners. Currently, there are no assays available enabling the study of on-target activity for all PAK isoforms in cells. To this end, we developed a series of NanoLuc- and HaloTag-based bioluminescence resonance energy transfer assays to quantify inhibitor target engagement and dimerization of PAK isoforms in living cells. Interestingly, we found evidence that inhibitors might promote the formation of group I PAK dimers. Thus, our data uncovered a live-cell mechanism by which inhibitors modulate this dimeric conformation and provide new tools for future PAK inhibitor design.

15 October 2024
Verified
Preprint
Open access
PDF file
NRNicolai D. Raig
Nicolai D. Raig
SKStefan Knapp
Stefan Knapp
This protocol outlines the synthesis of the LRRK2-selective type-2 kinase inhibitors RN277 and RN341, including structural characterization using nuclear magnetic resonance (NMR) and mass spectrometry (MS).

12 September 2024
Verified
Preprint
Open access
PDF file
NRNicolai D. Raig
Nicolai D. Raig
SKStefan Knapp
Stefan Knapp
With this enzymatic activity assay we were able to determine IC50 values of published inhibitors aswell as newly synthesized compounds that inhibit LRRK2. The assay is based on the in vitro phosphorylation reaction between the enzymatic active LRRK2(RCKW)-construct and the SOX-based substrate peptide (AQT0615 from AssayQuant Technologies).